The results of intraoperative consultations in 181 ductal carcinomas in Situ of the breast

✍ Scribed by Stewart F. Cramer

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 63 KB
• Volume: 82
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19980301)82:5<994::aid-cncr29>3.0.co;2-v

✦ Synopsis

agree with the authors that an adequate surgical event, unrelated to the skill of the pathologist who selects the block to be used for frozen section. margin is the most important factor affecting the prognosis for survival and local recurrence. The article also men-I suggest that this entrenched terminology is another example of ''the mystique of the mistake,'' 2 which has tions that the overall prognosis for MFH is the same as for osteosarcoma. We would like to make some remarks permeated the culture of surgical pathology since the time when giants like Lauren V. Ackerman and Arthur regarding the above-mentioned conclusions. First of all, was the high dose methotrexate (HD-MTX)-based che-Purdy Stout first began to teach about the many pitfalls in distinguishing benign from malignant lesions. Although motherapy, the so-called Rosen protocol, a breakthrough in the improvement in the limb-saving rate, the disease these remain important issues, 3,4 I suggest that the scientifically proper description of the phenomenon docu-free survival, and the overall survival of patients with an extremity osteosarcoma of bone? Recently, we demon-mented by Cheng et al. is ''sampling variation.'' Considering the current medicolegal climate and the modern strated that the limb-saving and survival rates for patients with MFH of bone improved dramatically after the intro-emphasis on quality assurance, 5 I would like to propose that Cancer undertake an editorial policy that requires duction of neoadjuvant chemotherapy for MFH of bone. Based on these results, it may be concluded that chemo-data that document substandard performance in macroscopic examination before allowing authors to use the therapy containing HD-MTX in addition to surgery is currently the optimal combined treatment for patients with term ''sampling error'' in lieu of ''sampling variation.'' this disease. 2